Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors.


Journal

NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891

Informations de publication

Date de publication:
17 Apr 2023
Historique:
received: 16 12 2022
accepted: 04 04 2023
medline: 18 4 2023
entrez: 17 4 2023
pubmed: 18 4 2023
Statut: epublish

Résumé

Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.

Identifiants

pubmed: 37069173
doi: 10.1038/s41523-023-00534-1
pii: 10.1038/s41523-023-00534-1
pmc: PMC10110597
doi:

Types de publication

Journal Article

Langues

eng

Pagination

27

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

JAMA Netw Open. 2021 Nov 1;4(11):e2133132
pubmed: 34739066
J Clin Oncol. 2020 Jun 10;38(17):1951-1962
pubmed: 32330069
NPJ Breast Cancer. 2022 Dec 20;8(1):131
pubmed: 36539444
JCO Oncol Pract. 2022 May;18(5):319-327
pubmed: 34637323
NPJ Breast Cancer. 2021 Jan 4;7(1):1
pubmed: 33397968
Cancers (Basel). 2022 Oct 11;14(20):
pubmed: 36291765
JAMA Oncol. 2022 Aug 1;8(8):1177-1183
pubmed: 35737367
NPJ Breast Cancer. 2021 Oct 12;7(1):137
pubmed: 34642348
JAMA Netw Open. 2022 Sep 1;5(9):e2231170
pubmed: 36107428
Lancet Oncol. 2021 Aug;22(8):1151-1161
pubmed: 34252375
Breast. 2021 Dec;60:62-69
pubmed: 34481367
Cancer Diagn Progn. 2022 May 3;2(3):316-323
pubmed: 35530657
Cancers (Basel). 2022 Dec 25;15(1):
pubmed: 36612123
Front Endocrinol (Lausanne). 2022 Aug 18;13:1000704
pubmed: 36060981
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782

Auteurs

Emma Zattarin (E)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Daniele Presti (D)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Luigi Mariani (L)

Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Caterina Sposetti (C)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Rita Leporati (R)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Alice Menichetti (A)

Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.

Chiara Corti (C)

Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Chiara Benvenuti (C)

IRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.

Giovanni Fucà (G)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Riccardo Lobefaro (R)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Francesca Ligorio (F)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.

Leonardo Provenzano (L)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Andrea Vingiani (A)

Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Marta Del Vecchio (M)

Division of Pharmacy, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy.

Gaia Griguolo (G)

Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
Department of Surgery, Oncology and Gastroenterology-DiSCOG, University of Padova, Padova, Italy.

Marianna Sirico (M)

Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014, Meldola, Italy.

Ottavia Bernocchi (O)

Farmacia Ospedaliera ASST Cremona, Viale Concordia 1, Cremona, Italy.

Antonio Marra (A)

Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.

Paola Zagami (P)

Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Elisa Agostinetto (E)

IRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.
Institut Jules Bordet and l'Université Libre de Bruxelles, Bruxelles, Belgium.

Flavia Jacobs (F)

IRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.

Pierluigi Di Mauro (P)

Medical Oncology Unit, ASST Spedali Civili, Brescia, Italy.

Andrea Esposito (A)

Medical Oncology Unit, ASST Spedali Civili, Brescia, Italy.

Carlo Alberto Giorgi (CA)

Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.

Luca Lalli (L)

Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Laura Boldrini (L)

Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Pier Paolo Berton Giacchetti (PPB)

Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Ambra Carnevale Schianca (AC)

Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Valentina Guarneri (V)

Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
Department of Surgery, Oncology and Gastroenterology-DiSCOG, University of Padova, Padova, Italy.

Rebecca Pedersini (R)

Medical Oncology Unit, ASST Spedali Civili, Brescia, Italy.

Agnese Losurdo (A)

IRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.

Alberto Zambelli (A)

IRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.

Daniele Generali (D)

Breast Cancer Unit & Translational Research Unit, ASST Cremona, Cremona, Italy.
Department of Medical, Surgery and Health Sciences, University of Trieste, 34147, Trieste, Italy.

Carmen Criscitiello (C)

Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Giuseppe Curigliano (G)

Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Giancarlo Pruneri (G)

Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Filippo de Braud (F)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Maria Vittoria Dieci (MV)

Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
Department of Surgery, Oncology and Gastroenterology-DiSCOG, University of Padova, Padova, Italy.

Claudio Vernieri (C)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. claudio.vernieri@istitutotumori.mi.it.
IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy. claudio.vernieri@istitutotumori.mi.it.

Classifications MeSH